{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Diefenbach CS"],"funding":["NCI NIH HHS"],"pagination":["530-8"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC4881845"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["171(4)"],"pubmed_abstract":["The International Prognostic Score (IPS-7) is the most commonly used risk stratification tool for advanced Hodgkin lymphoma (HL), however recent studies suggest the IPS-7 is less discriminating due to improved outcomes with contemporary therapy. We evaluated the seven variables for IPS-7 recorded at study entry for 854 patients enrolled on Eastern Cooperative Oncology Group 2496 trial. Univariate and multivariate Cox models were used to assess their prognostic ability for freedom from progression (FFP) and overall survival (OS). The IPS-7 remained prognostic however its prognostic range has narrowed. On multivariate analysis, two factors (age, stage) remained significant for FFP and three factors (age, stage, haemoglobin level) for OS. An alternative prognostic index, the IPS-3, was constructed using age, stage and haemoglobin level, which provided four distinct risk groups [FFP (P = 0·0001) and OS (P < 0·0001)]. IPS-3 outperformed the IPS-7 on risk prediction for both FFP and OS by model fit and discrimination criteria. Using reclassification calibration, 18% of IPS-7 low risk patients were re-classified as intermediate risk and 13% of IPS-7 intermediate risk patients as low risk. For patients with advanced HL, the IPS-3 may provide a simpler and more accurate framework for risk assessment in the modern era. Validation of these findings in other large data sets is planned."],"journal":["British journal of haematology"],"pubmed_title":["Evaluation of the International Prognostic Score (IPS-7) and a Simpler Prognostic Score (IPS-3) for advanced Hodgkin lymphoma in the modern era."],"pmcid":["PMC4881845"],"funding_grant_id":["U10 CA066636","CA180799","N01 CA032102","CA66636","U10 CA032102","CA180794","U10 CA017145","U10 CA180790","CA180790","U10 CA011083","U10 CA077597","U10 CA027525","U10 CA180794","U10 CA077658","U10 CA046282","CA17145","CA77658","U10 CA180850","CA21076","CA77597","P30 CA060553","U10 CA180799","CA11083","CA21115","U10 CA180816","CA23318","CA180816","U10 CA013650","CA13650","CA180820","U10 CA077440","U10 CA021115","U10 CA023318","CA33601","U10 CA077202","CA31946","CA46282","U10 CA031946","CA27525","U10 CA021076","U10 CA180820","U10 CA180846","U10 CA033601","CA77202","U10 CA180888","CA77440"],"pubmed_authors":["Habermann TM","Li H","Wagner H","Tuscano JM","Friedberg JW","Diefenbach CS","Horning SJ","Hong F","Fisher RI","Gordon LI","Kahl BS","Cheson BD","Advani RH","Gascoyne RD","Bartlett NL","Crump M","Hoppe RT","Stewart DA","Blum KA","Stiff PJ"],"additional_accession":[]},"is_claimable":false,"name":"Evaluation of the International Prognostic Score (IPS-7) and a Simpler Prognostic Score (IPS-3) for advanced Hodgkin lymphoma in the modern era.","description":"The International Prognostic Score (IPS-7) is the most commonly used risk stratification tool for advanced Hodgkin lymphoma (HL), however recent studies suggest the IPS-7 is less discriminating due to improved outcomes with contemporary therapy. We evaluated the seven variables for IPS-7 recorded at study entry for 854 patients enrolled on Eastern Cooperative Oncology Group 2496 trial. Univariate and multivariate Cox models were used to assess their prognostic ability for freedom from progression (FFP) and overall survival (OS). The IPS-7 remained prognostic however its prognostic range has narrowed. On multivariate analysis, two factors (age, stage) remained significant for FFP and three factors (age, stage, haemoglobin level) for OS. An alternative prognostic index, the IPS-3, was constructed using age, stage and haemoglobin level, which provided four distinct risk groups [FFP (P = 0·0001) and OS (P < 0·0001)]. IPS-3 outperformed the IPS-7 on risk prediction for both FFP and OS by model fit and discrimination criteria. Using reclassification calibration, 18% of IPS-7 low risk patients were re-classified as intermediate risk and 13% of IPS-7 intermediate risk patients as low risk. For patients with advanced HL, the IPS-3 may provide a simpler and more accurate framework for risk assessment in the modern era. Validation of these findings in other large data sets is planned.","dates":{"release":"2015-01-01T00:00:00Z","publication":"2015 Nov","modification":"2020-10-29T14:53:03Z","creation":"2019-03-27T02:14:36Z"},"accession":"S-EPMC4881845","cross_references":{"pubmed":["26343802"],"doi":["10.1111/bjh.13634"]}}